期刊文献+

嘉兴路街道社区60岁及以上人群抗骨质疏松药物使用调查

Investigating the usage of anti-osteoporosis drugs in people over the age of 60 of JiaXin Road communities
下载PDF
导出
摘要 目的调查虹口区嘉兴路街道社区60岁及以上老年人群的抗骨质疏松药物使用现状,为临床合理用药提供参考。方法随机抽样年龄在60岁及以上人群1000例为调查对象,进行问卷调查,同时给予目标人群非强制性免费跟骨骨密度检测。结果在995份有效问卷中,钙制剂、维生素D制剂、中药类、双膦酸盐类、降钙素类分列抗骨质疏松药物使用前五位,分别占总人数百分比为18.79%、9.65%、3.52%、2.11%、0.80%。骨密度筛查显示74.6%所检测的目标人群骨密度不达标。结论抗骨质疏松药物的使用率远没有匹配骨质疏松患病率;抗骨质疏松药物应用情况调查对促进抗骨质疏松药的合理应用具有重要意义。 Objective To investigate the usage of anti-osteoporosis drugs in people over the age of 60 in JiaXin Road communities of HongKou District and to provide a reference for clinical use. Methods Randomly extract 1000 people ( ≥60 years) in JiaXin Road communities with questionnaire survey. Provide non-mandatory and free calcaneus' bone mineral density measurement to the target population. Results In the 995 valid questionnaires, the calcium preparation, the Vitamin D preparation, Traditional Chinese Medicine, Bisphosphonates and calcitonin point out the top five sharing of anti-osteoporosis drugs to be used. The respective percentage of the total number is 18,79%, 9.65%, 3.52%, 2.11%, 0.80 %. Bone mineral density screening shows that 74.6 percent of the target population who were detected is under the stan- dard. Conclusion The usage of anti-osteoporosis drugs are far below the morbidity rate. The application of anti- osteoporosis drugs can promote the rational use with great significance.
出处 《老年医学与保健》 CAS 2013年第6期391-394,共4页 Geriatrics & Health Care
基金 上海市虹口区卫生局支持课题基金(虹卫1104-51)
关键词 骨质疏松 抗骨质疏松药 骨密度 Osteoporosis Anti-osteoporosis drugs Bone mineral density
  • 相关文献

参考文献8

二级参考文献44

  • 1马慧萍,贾正平,葛欣,陈克明.骨质疏松症的药物防治研究现状[J].中国药师,2004,7(10):816-818. 被引量:14
  • 2杨宗炎,王颍.2001年~2003年上海市骨质疏松症药物应用分析[J].中国医院用药评价与分析,2005,5(1):27-30. 被引量:4
  • 3林琳,万晓慧,丁岩.激素替代疗法对绝经后妇女乳腺的影响[J].新疆医科大学学报,2006,29(8):724-726. 被引量:3
  • 4丁海青.2005—2006年我院抗菌药物应用情况分析[J].中国药业,2007,16(9):36-37. 被引量:8
  • 5Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a system artic-review. CMAJ, 2006,175(1):52-59.
  • 6Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, highdose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.J Clin Endocrinol Metab, 2003,88(2):569-575.
  • 7Solomon DH, Finhelstein JS, Wang PS, et aL Statin lipidlowefing drugs and bone mineral density. Pharmacoepidemiol Drug Saf, 2005,14:219-226.
  • 8Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int, 2005,16(8):990-998.
  • 9D'Amore M, Bottalico C, D'Amore S, et al. Sex hormones and male osteoporosis.A physiologic prospective for prevention and therapy. Minerva Med, 2000,91(3):283-289.
  • 10Khosla S, Melton LJ, Robb RA, et al. Relationship of volumetric BMD and structural parameters at diffierent skeletal sites to sex steroid levels in men. J Bone Miner Res, 2005,20:730- 740.

共引文献196

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部